Tactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results
Tactile Medical (Nasdaq: TCMD) reported Q3 2025 results on November 3, 2025, with total revenue $85.8M (+17% YoY), gross margin 76%, net income $8.2M ($0.36 diluted) and Adjusted EBITDA $14.4M. The company repaid its $24.0M term loan, refinanced its revolver to $40M capacity, and authorized a $25M share repurchase program (expires Nov 3, 2027). Full‑year 2025 guidance was raised to $317M–$321M revenue and $38M–$39.5M adjusted EBITDA. Cash was $66.0M at Sept 30, 2025.
Tactile Medical (Nasdaq: TCMD) ha riportato i risultati del terzo trimestre 2025 il 3 novembre 2025, con ricavi totali di 85,8 milioni di dollari (+17% su base annua), margine lordo del 76%, utile netto di 8,2 milioni di dollari (0,36 dollari diluiti) e EBITDA rettificato di 14,4 milioni di dollari. L’azienda ha rimborsato il prestito a termine di 24,0 milioni di dollari, rifinanziato il revolver a una capacità di 40 milioni di dollari e autorizzato un programma di riacquisto azioni da 25 milioni di dollari (scadenza 3 novembre 2027). Le previsioni per l’intero 2025 sono state innalzate a ricavi di 317–321 milioni di dollari e EBITDA rettificato di 38–39,5 milioni di dollari. La liquidità ammontava a 66,0 milioni di dollari al 30 settembre 2025.
Tactile Medical (Nasdaq: TCMD) informó los resultados del tercer trimestre de 2025 el 3 de noviembre de 2025, con los ingresos totales de 85,8 millones de dólares (+17% interanual), margen bruto del 76%, beneficio neto de 8,2 millones de dólares (0,36 dólares diluidos) y EBITDA ajustado de 14,4 millones de dólares. La empresa pagó su préstamo a término de 24,0 millones de dólares, refinanció su revolver a una capacidad de 40 millones de dólares y autorizó un programa de recompra de acciones de 25 millones de dólares (vence el 3 de noviembre de 2027). Las estimaciones para todo 2025 se elevaron a ingresos de 317–321 millones de dólares y EBITDA ajustado de 38–39,5 millones de dólares. El efectivo era de 66,0 millones de dólares al 30 de septiembre de 2025.
Tactile Medical (나스닥: TCMD)는 2025년 11월 3일 2025년 3분기 실적을 발표했고, 총매출 8,580만 달러(+전년 대비 17%), 총이익률 76%, 순이익 820만 달러 (희석 주당 0.36달러) 및 조정 EBITDA 1,440만 달러를 기록했습니다. 회사는 2,400만 달러의 기간 대출을 상환하고, revolver를 4천만 달러 규모로 재융자했으며, 2,500만 달러의 자사주 매입 계획을 승인했습니다(만료일 2027년 11월 3일). 2025년 전체 가이던스는 매출 317–321백만 달러 및 조정 EBITDA 38–39.5백만 달러로 상향되었습니다. 현금 보유액은 66,0백만 달러였으며 2025년 9월 30일 기준입니다.
Tactile Medical (Nasdaq : TCMD) a publié les résultats du troisième trimestre 2025 le 3 novembre 2025, avec un chiffre d'affaires total de 85,8 millions de dollars (+17% sur un an), une marge brute de 76%, un bénéfice net de 8,2 millions de dollars (0,36 dollar dilué) et un EBITDA ajusté de 14,4 millions de dollars. L'entreprise a remboursé son prêt à terme de 24,0 millions de dollars, refinancé son revolver à une capacité de 40 millions de dollars et a autorisé un programme de rachat d'actions de 25 millions de dollars (expiration le 3 novembre 2027). Les prévisions pour l'ensemble de l'année 2025 ont été relevées à un chiffre d'affaires de 317–321 millions de dollars et un EBITDA ajusté de 38–39,5 millions de dollars. La trésorerie était de 66,0 millions de dollars au 30 septembre 2025.
Tactile Medical (Nasdaq: TCMD) berichtete am 3. November 2025 über die Ergebnisse des dritten Quartals 2025 mit dem Gesamtumsatz von 85,8 Mio. USD (+17% YoY), Bruttomarge von 76%, Nettoeinkommen von 8,2 Mio. USD (0,36 USD verwässert) und angepasstem EBITDA von 14,4 Mio. USD. Das Unternehmen hat den 24,0 Mio. USD Term Loan getilgt, seinen Revolver auf 40 Mio. USD Kapazität refinanziert und ein Aktienrückkaufprogramm in Höhe von 25 Mio. USD genehmigt (läuft am 3. November 2027 ab). Die Guidance für das Gesamtjahr 2025 wurde auf Umsatz von 317–321 Mio. USD und angepasstes EBITDA von 38–39,5 Mio. USD erhöht. Die Barmittel betrugen zum 30. September 2025 66,0 Mio. USD.
Tactile Medical (ناسداك: TCMD) أصدرت نتائج الربع الثالث من عام 2025 في 3 نوفمبر 2025، مع إجمالي الإيرادات 85.8 مليون دولار (+17% سنويًا)، هامش إجمالي 76%، صافي الدخل 8.2 مليون دولار (0.36 دولار مُخفّض) و EBITDA المعدل 14.4 مليون دولار. سددت الشركة قرض التمويل لمدة 24.0 مليون دولار، وأعادت تمويل revolver إلى قدرة 40 مليون دولار، ووافقت على برنامج إعادة شراء أسهم بقيمة 25 مليون دولار (ينتهي في 3 نوفمبر 2027). رفعت التوجيهات للعام 2025 بالكامل إلى إيرادات 317–321 مليون دولار و EBITDA المعدل 38–39.5 مليون دولار. النقدية كانت 66.0 مليون دولار في 30 سبتمبر 2025.
- Total revenue +17% in Q3 2025 to $85.8M
- Adjusted EBITDA $14.4M in Q3 2025
- Net income $8.2M in Q3 2025 ($0.36 diluted)
- Repaid $24.0M term loan on July 31, 2025
- Board authorized $25.0M share repurchase program
- Raised 2025 revenue guidance to $317M–$321M
- Cash balance down to $66.0M from $94.4M at year-end 2024
- Operating expenses increased 13% in Q3 2025
Insights
Tactile Medical reported clear sequential strength: revenue, margins, net income, adjusted EBITDA and guidance all improved, plus a $25M buyback and debt retirement.
The company grew third-quarter revenue to
Risks and dependencies are explicit in the disclosures: operating expenses rose to
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2025 and announced the adoption of a second share repurchase program.
Third Quarter 2025 Summary & Recent Business Highlights:
- Total revenue increased
17% year-over-year to$85.8 million - Gross margin of
76% versus75% in Q3 2024 - Net income of
$8.2 million versus$5.2 million in Q3 2024 - Adjusted EBITDA of
$14.4 million versus$10.7 million in Q3 2024 - Announced six-month data demonstrating sustained benefits of Flexitouch® Plus as a first-line therapy in treating lymphedema in head and neck cancer patients
- Repaid the full outstanding principal balance of
$24.0 million under the Company’s term loan - Authorized a second program to repurchase up to
$25.0 million of the Company’s common stock
“Tactile Medical delivered strong third quarter results, reflecting continued progress across our business transformation and product innovation initiatives”, said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Our go-to-market strategies and differentiated products are driving market leadership and top-line growth, and we are beginning to see leverage in our internal business operations and processes. We are aligned on our strategy, focused on execution, and well positioned to capitalize on the strength of our organization and improving market conditions.”
“Building on this momentum, we are increasingly confident in the trajectory of our business and our ability to execute our financial and operational initiatives, as reflected in our revenue and adjusted EBITDA guidance updates and the establishment of a new stock repurchase program. We look forward to closing out 2025 in a strong position and continuing to build momentum for 2026 and beyond.”
Third Quarter 2025 Financial Results
Total revenue in the third quarter of 2025 increased
Gross profit in the third quarter of 2025 increased
Operating expenses in the third quarter of 2025 increased
Operating income was
Income tax expense was
Net income in the third quarter of 2025 was
Weighted average shares used to compute diluted net income per share were 22.5 million and 24.3 million for the third quarters of 2025 and 2024, respectively.
Adjusted EBITDA was
First Nine Months 2025 Financial Results
Total revenue for the nine months ended September 30, 2025, increased
Net income for the nine months ended September 30, 2025, was
Weighted average shares used to compute diluted net income per share were 23.3 million and 24.1 million for the nine months ended September 30, 2025 and 2024, respectively.
Adjusted EBITDA was
Balance Sheet Summary
As of September 30, 2025, the Company had
On July 31, 2025, the Company paid the full outstanding principal balance of
Share Repurchase Program
The Company also announced today that the Board of Directors of the Company authorized a program to repurchase up to
2025 Financial Outlook
The Company is updating its 2025 financial outlook and now expects full year 2025 total revenue in the range of
The Company now also expects full year 2025 adjusted EBITDA in the range of
Conference Call
Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13755883. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements, including guidance for the full year 2025. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions, including inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, the Company’s products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net income, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense and plus executive transition costs. Reconciliation of this non-GAAP financial measure to its most directly comparable GAAP measure is included in this press release.
This non-GAAP financial measure is presented because the Company believes it is a useful indicator of its operating performance. Management uses this measure principally as a measure of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes this measure is useful to investors as supplemental information and because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes this non-GAAP financial measure is useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.
The non-GAAP financial measure presented in this release should not be considered as an alternative to, or superior to, its respective GAAP financial measure, as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
| Tactile Systems Technology, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
| (In thousands, except share and per share data) | 2025 | 2024 | ||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash | $ | 65,965 | $ | 94,367 | ||||
| Accounts receivable, net | 37,257 | 44,937 | ||||||
| Net investment in leases | 14,843 | 14,540 | ||||||
| Inventories | 16,084 | 18,666 | ||||||
| Prepaid expenses and other current assets | 7,250 | 5,053 | ||||||
| Total current assets | 141,399 | 177,563 | ||||||
| Non-current assets | ||||||||
| Property and equipment, net | 5,460 | 5,603 | ||||||
| Right of use operating lease assets | 14,751 | 16,633 | ||||||
| Intangible assets, net | 40,023 | 42,789 | ||||||
| Goodwill | 31,063 | 31,063 | ||||||
| Deferred income taxes | 16,745 | 18,311 | ||||||
| Other non-current assets | 9,736 | 5,962 | ||||||
| Total non-current assets | 117,778 | 120,361 | ||||||
| Total assets | $ | 259,177 | $ | 297,924 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 7,989 | $ | 5,648 | ||||
| Note payable | — | 2,956 | ||||||
| Accrued payroll and related taxes | 14,727 | 17,923 | ||||||
| Accrued expenses | 7,862 | 7,780 | ||||||
| Income taxes payable | 1,200 | 270 | ||||||
| Operating lease liabilities | 3,144 | 2,980 | ||||||
| Other current liabilities | 4,264 | 3,147 | ||||||
| Total current liabilities | 39,186 | 40,704 | ||||||
| Non-current liabilities | ||||||||
| Note payable, non-current | — | 23,220 | ||||||
| Accrued warranty reserve, non-current | 1,121 | 1,209 | ||||||
| Income taxes payable, non-current | 334 | 239 | ||||||
| Operating lease liabilities, non-current | 13,587 | 15,955 | ||||||
| Total non-current liabilities | 15,042 | 40,623 | ||||||
| Total liabilities | 54,228 | 81,327 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 22 | 24 | ||||||
| Additional paid-in capital | 160,621 | 180,719 | ||||||
| Retained earnings | 44,306 | 35,854 | ||||||
| Total stockholders’ equity | 204,949 | 216,597 | ||||||
| Total liabilities and stockholders’ equity | $ | 259,177 | $ | 297,924 | ||||
| Tactile Systems Technology, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | ||||||||||||||||
| Sales revenue | $ | 76,890 | $ | 63,168 | $ | 199,890 | $ | 180,742 | ||||||||
| Rental revenue | 8,865 | 9,925 | 26,038 | 26,657 | ||||||||||||
| Total revenue | 85,755 | 73,093 | 225,928 | 207,399 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Cost of sales revenue | 17,896 | 15,603 | 49,270 | 46,810 | ||||||||||||
| Cost of rental revenue | 2,858 | 2,703 | 7,518 | 8,270 | ||||||||||||
| Total cost of revenue | 20,754 | 18,306 | 56,788 | 55,080 | ||||||||||||
| Gross profit | ||||||||||||||||
| Gross profit - sales revenue | 58,994 | 47,565 | 150,620 | 133,932 | ||||||||||||
| Gross profit - rental revenue | 6,007 | 7,222 | 18,520 | 18,387 | ||||||||||||
| Gross profit | 65,001 | 54,787 | 169,140 | 152,319 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 29,809 | 26,838 | 87,364 | 82,803 | ||||||||||||
| Research and development | 2,191 | 2,417 | 5,950 | 6,794 | ||||||||||||
| Reimbursement, general and administrative | 21,442 | 18,118 | 63,474 | 51,158 | ||||||||||||
| Intangible asset amortization | 596 | 633 | 1,848 | 1,898 | ||||||||||||
| Total operating expenses | 54,038 | 48,006 | 158,636 | 142,653 | ||||||||||||
| Income from operations | 10,963 | 6,781 | 10,504 | 9,666 | ||||||||||||
| Interest income | 667 | 969 | 2,412 | 2,437 | ||||||||||||
| Interest expense | (193 | ) | (517 | ) | (1,027 | ) | (1,614 | ) | ||||||||
| Other income | — | — | 1 | 9 | ||||||||||||
| Income before income taxes | 11,437 | 7,233 | 11,890 | 10,498 | ||||||||||||
| Income tax expense | 3,228 | 2,078 | 3,438 | 3,254 | ||||||||||||
| Net income | $ | 8,209 | $ | 5,155 | $ | 8,452 | $ | 7,244 | ||||||||
| Net income per common share | ||||||||||||||||
| Basic | $ | 0.37 | $ | 0.21 | $ | 0.37 | $ | 0.30 | ||||||||
| Diluted | $ | 0.36 | $ | 0.21 | $ | 0.36 | $ | 0.30 | ||||||||
| Weighted-average common shares used to compute net income per common share | ||||||||||||||||
| Basic | 22,318,570 | 23,985,364 | 23,035,461 | 23,842,049 | ||||||||||||
| Diluted | 22,513,140 | 24,254,176 | 23,304,900 | 24,070,084 | ||||||||||||
| Tactile Systems Technology, Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| (In thousands) | 2025 | 2024 | ||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 8,452 | $ | 7,244 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 5,023 | 5,079 | ||||||
| Deferred income taxes | 1,566 | (341 | ) | |||||
| Stock-based compensation expense | 5,819 | 5,969 | ||||||
| Loss on disposal of property and equipment and intangibles | 68 | 308 | ||||||
| Changes in assets and liabilities, net of acquisition: | ||||||||
| Accounts receivable, net | 7,680 | 3,203 | ||||||
| Net investment in leases | (303 | ) | 242 | |||||
| Inventories | 2,582 | 1,351 | ||||||
| Income taxes payable | 1,025 | (807 | ) | |||||
| Prepaid expenses and other assets | (5,971 | ) | (1,844 | ) | ||||
| Right of use operating lease assets | (322 | ) | (18 | ) | ||||
| Accounts receivable, non-current | — | 7,308 | ||||||
| Accounts payable | 2,117 | 582 | ||||||
| Accrued payroll and related taxes | (3,196 | ) | (3,703 | ) | ||||
| Accrued expenses and other liabilities | 975 | (251 | ) | |||||
| Net cash provided by operating activities | 25,515 | 24,322 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (1,870 | ) | (1,932 | ) | ||||
| Proceeds from sale of property and equipment | — | 12 | ||||||
| Intangible assets expenditures | (88 | ) | (85 | ) | ||||
| Net cash used in investing activities | (1,958 | ) | (2,005 | ) | ||||
| Cash flows from financing activities | ||||||||
| Payments on note payable | (26,250 | ) | (2,250 | ) | ||||
| Proceeds from exercise of common stock options | 10 | 2 | ||||||
| Proceeds from the issuance of common stock from the employee stock purchase plan | 843 | 1,044 | ||||||
| Payments for repurchases of common stock | (26,562 | ) | — | |||||
| Net cash used in financing activities | (51,959 | ) | (1,204 | ) | ||||
| Net (decrease) increase in cash | (28,402 | ) | 21,113 | |||||
| Cash – beginning of period | 94,367 | 61,033 | ||||||
| Cash – end of period | $ | 65,965 | $ | 82,146 | ||||
| Supplemental cash flow disclosure | ||||||||
| Cash paid for interest | $ | 836 | $ | 1,612 | ||||
| Cash paid for taxes | $ | 899 | $ | 4,428 | ||||
| Accrued excise tax on stock repurchases | $ | 210 | $ | — | ||||
| Capital expenditures incurred but not yet paid | $ | 224 | $ | 49 | ||||
The following table summarizes revenue by product line for the three and nine months ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | ||||||||||||||||
| Lymphedema products | $ | 72,381 | $ | 65,282 | $ | 188,905 | $ | 182,278 | ||||||||
| Airway clearance products | 13,374 | 7,811 | 37,023 | 25,121 | ||||||||||||
| Total | $ | 85,755 | $ | 73,093 | $ | 225,928 | $ | 207,399 | ||||||||
| Percentage of total revenue | ||||||||||||||||
| Lymphedema products | 84 | % | 89 | % | 84 | % | 88 | % | ||||||||
| Airway clearance products | 16 | % | 11 | % | 16 | % | 12 | % | ||||||||
| Total | 100 | % | 100 | % | 100 | % | 100 | % | ||||||||
The following table contains a reconciliation of net income to Adjusted EBITDA for the three and nine months ended September 30, 2025 and 2024, as well as the dollar and percentage change between the comparable periods:
| Tactile Systems Technology, Inc. | ||||||||||||||||||||||||||||||
| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||
| Three Months Ended | Increase | Nine Months Ended | Increase | |||||||||||||||||||||||||||
| September 30, | (Decrease) | September 30, | (Decrease) | |||||||||||||||||||||||||||
| (Dollars in thousands) | 2025 | 2024 | $ | % | 2025 | 2024 | $ | % | ||||||||||||||||||||||
| Net Income | $ | 8,209 | $ | 5,155 | $ | 3,054 | 59 | % | $ | 8,452 | $ | 7,244 | $ | 1,208 | 17 | % | ||||||||||||||
| Interest (income) expense, net | (474 | ) | (452 | ) | (22 | ) | 5 | % | (1,385 | ) | (823 | ) | (562 | ) | 68 | % | ||||||||||||||
| Income tax expense | 3,228 | 2,078 | 1,150 | 55 | % | 3,438 | 3,254 | 184 | 6 | % | ||||||||||||||||||||
| Depreciation and amortization | 1,638 | 1,734 | (96 | ) | (6 | )% | 5,023 | 5,079 | (56 | ) | (1 | )% | ||||||||||||||||||
| Stock-based compensation | 1,814 | 2,070 | (256 | ) | (12 | )% | 5,819 | 5,969 | (150 | ) | (3 | )% | ||||||||||||||||||
| Executive transition costs | — | 136 | (136 | ) | (100 | )% | 491 | 111 | 380 | N.M. | % | |||||||||||||||||||
| Adjusted EBITDA | $ | 14,415 | $ | 10,721 | $ | 3,694 | 34 | % | $ | 21,838 | $ | 20,834 | $ | 1,004 | 5 | % | ||||||||||||||
The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2024:
| Tactile Systems Technology, Inc. | ||||
| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | ||||
| (Unaudited) | ||||
| Year Ended | ||||
| (Dollars in thousands) | December 31, 2024 | |||
| Net income | $ | 16,960 | ||
| Interest (income) expense, net | (1,299 | ) | ||
| Income tax expense | 6,529 | |||
| Depreciation and amortization | 6,793 | |||
| Stock-based compensation | 7,819 | |||
| Executive transition costs | 248 | |||
| Adjusted EBITDA | $ | 37,050 | ||
The following table contains a reconciliation of GAAP net income guidance range to the Adjusted EBITDA guidance range for the twelve months ended December 31, 2025:
| Tactile Systems Technology, Inc. | ||||||||
| Reconciliation of FY 2025 GAAP Net Income to Adjusted EBITDA Guidance | ||||||||
| (Unaudited) | ||||||||
| Twelve Months Ended | ||||||||
| December 31, 2025 | ||||||||
| (Dollars in thousands) | Low | High | ||||||
| Net income | $ | 17,900 | $ | 19,000 | ||||
| Interest income, net | (1,800 | ) | (1,800 | ) | ||||
| Income tax expense | 7,000 | 7,400 | ||||||
| Depreciation and amortization | 6,600 | 6,600 | ||||||
| Stock-based compensation | 7,800 | 7,800 | ||||||
| Executive transition costs | 500 | 500 | ||||||
| Adjusted EBITDA | $ | 38,000 | $ | 39,500 | ||||
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com
FAQ
What were Tactile Medical (TCMD) Q3 2025 revenue and net income?
How did TCMD’s Adjusted EBITDA perform in Q3 2025?
What is the size and expiry of the TCMD share repurchase program announced Nov 3, 2025?
Did TCMD change full‑year 2025 guidance on Nov 3, 2025?
What debt actions did TCMD take in 2025 that affect shareholders?
How might the $25M buyback affect TCMD shareholders in the near term?
